Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for Aldeyra Therapeutics in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst M. Caufield anticipates that the biotechnology company will earn ($0.25) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Aldeyra Therapeutics' current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics' Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at $0.08 EPS, FY2028 earnings at $0.48 EPS and FY2029 earnings at $1.00 EPS.
Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.30).
Aldeyra Therapeutics Stock Performance
Shares of Aldeyra Therapeutics stock traded up $0.27 on Thursday, hitting $6.62. 747,029 shares of the company were exchanged, compared to its average volume of 447,785. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. The company has a 50-day moving average price of $5.61 and a 200 day moving average price of $5.42. Aldeyra Therapeutics has a 1-year low of $2.71 and a 1-year high of $6.92.
Hedge Funds Weigh In On Aldeyra Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of ALDX. US Bancorp DE acquired a new position in shares of Aldeyra Therapeutics during the 3rd quarter worth about $30,000. Hsbc Holdings PLC acquired a new position in Aldeyra Therapeutics during the 4th quarter worth approximately $52,000. Balyasny Asset Management L.P. purchased a new stake in shares of Aldeyra Therapeutics during the 4th quarter worth $56,000. Paloma Partners Management Co acquired a new position in Aldeyra Therapeutics during the third quarter worth about $62,000. Finally, Catalyst Funds Management Pty Ltd boosted its position in Aldeyra Therapeutics by 2,083.3% during the fourth quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company's stock worth $65,000 after purchasing an additional 12,500 shares in the last quarter. 59.71% of the stock is currently owned by hedge funds and other institutional investors.
About Aldeyra Therapeutics
(
Get Free Report)
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Read More
Before you consider Aldeyra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aldeyra Therapeutics wasn't on the list.
While Aldeyra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
